Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.

Pramil, Elodie et al.·Blood advances·2019·
RPEP-044272019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Published In:
Blood advances, 3(20), 2920-2933 (2019)
Database ID:
RPEP-04427

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-04427·https://rethinkpeptides.com/research/RPEP-04427

APA

Pramil, Elodie; Herbi Bastian, Linda; Denèfle, Thomas; Nemati, Fariba; Xiao, Malina; Lardé, Eva; Maloum, Karim; Roos-Weil, Damien; Chapiro, Elise; Le Garff-Tavernier, Magali; Davi, Frédéric; Decaudin, Didier; Sarfati, Marika; Nguyen-Khac, Florence; Merle-Béral, Hélène; Karoyan, Philippe; Susin, Santos A. (2019). Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.. Blood advances, 3(20), 2920-2933. https://doi.org/10.1182/bloodadvances.2019000350

MLA

Pramil, Elodie, et al. "Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.." Blood advances, 2019. https://doi.org/10.1182/bloodadvances.2019000350

RethinkPeptides

RethinkPeptides Research Database. "Targeting chronic lymphocytic leukemia with N-methylated thr..." RPEP-04427. Retrieved from https://rethinkpeptides.com/research/pramil-2019-targeting-chronic-lymphocytic-leukemia

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.